Observe Medical (OBSRV) Company presentation summary

Strategic vision and platform development

• Focus on scalable, profitable growth through product development, regulatory performance, and effective manufacturing.

• Emphasis on commercialization and portfolio development of proprietary products.

• Platform aims to support innovative Nordic medtech start-ups lacking commercial, regulatory, and manufacturing capacity.

• M&A opportunities to integrate and optimize new assets on the platform.

• Prioritizes patient welfare, health economics, and data accuracy.

Commercial strategy and market execution

• Significant milestones include product launches, regulatory integration, and asset acquisitions from 2019 to 2025.

• Market penetration strategy leverages the UnoMeter and Sippi product families, targeting ICU urine output measurement.

• Upselling and portfolio expansion to maximize market potential and margins.

• Established sales in Europe, South America, and Asia, with further expansion planned.

• 85% geographical coverage achieved, with ongoing tender processes in key markets.

Product innovation and clinical impact

• Sippi® automates urine output monitoring, reducing infection risk, improving data accuracy, and saving staff time.

• UnoMeter Safeti Plus and upcoming Safeti Max feature patented infection control technology to address CAUTI.

• Clinical documentation and CE certification support product credibility and market access.

• Pilot studies and regulatory work underway for new product launches in 2025.

• Products address significant clinical challenges in ICU, including infection prevention and operational efficiency.